Simulations Plus Partners with NVIDIA to Enhance Drug Development Simulations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Simulations Plus (SLP) announced the launch of a technical collaboration with NVIDIA (NVDA) focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simulations Plus' validated scientific engines across physiologically-based pharmacokinetics, pharmacokinetics/pharmacodynamics, and quantitative systems pharmacology with NVIDIA AI infrastructure to accelerate and scale simulation cycles, parameter exploration, and virtual population studies. Together, these capabilities address two core constraints in model-informed drug development: reducing manual, expertise-driven work and enabling large-scale exploration of model structures and parameters in parallel-shifting modeling from a sequential process to a more iterative, data-informed workflow operating at program-relevant timelines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 16.650
Low
19.00
Averages
19.00
High
19.00
Current: 16.650
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating whether Simulation Plus, Inc. violated securities laws and breached fiduciary duties, indicating potential severe governance issues that could undermine investor confidence.
- Declining Financial Performance: In Q3 FY2025, Simulation Plus reported a net loss of $67.3 million and a non-cash impairment charge of $77.2 million, reflecting operational challenges amid market uncertainties that may lead to further stock price declines.
- Auditor Dismissal Impact: The company dismissed its auditor Grant Thornton LLP due to the inability to finalize its Form 10-Q, highlighting significant deficiencies in internal controls and financial reporting that could trigger additional legal liabilities and shareholder claims.
- Stock Price Volatility: Following the financial reports in June and July 2025, Simulation Plus's stock price fell over 24% and 26%, respectively, raising investor concerns about the company's future prospects and potentially prompting more investors to seek legal recourse.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on whether the company made false or misleading statements regarding its financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: In June 2025, Simulations Plus revised its full-year revenue guidance down from $90 million to $93 million to a range of $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to a stock price drop of over 24%.
- Significant Financial Losses: In July 2025, Simulations Plus reported a third-quarter net loss of $67.3 million, or $3.35 per diluted share, which included a $77.2 million non-cash impairment charge, indicating a severe deterioration in the company's financial health.
- Audit Firm Dismissal: The company's Audit Committee dismissed Grant Thornton LLP due to unresolved issues related to financial reporting, causing the stock price to plummet nearly 26%, from $17.47 to $12.97 per share, exacerbating investor concerns about the company's governance and financial integrity.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating Simulation Plus, Inc. to determine whether certain officers and directors violated securities laws and fiduciary duties, potentially exposing the company to legal risks and reputational damage.
- Declining Financial Performance: On July 14, 2025, Simulation Plus reported a net loss of $67.3 million for the third quarter, along with a $77.2 million non-cash impairment charge, indicating financial vulnerability amid market uncertainties that could affect future funding capabilities.
- Auditor Dismissal: The company disclosed the dismissal of its auditor, Grant Thornton LLP, due to the inability to finalize certain matters in financial reporting, raising investor concerns about internal controls and financial transparency, which may exacerbate shareholder anxiety.
- Stock Price Volatility: Following the earnings announcements on June 11 and July 15, Simulation Plus's stock price plummeted over 24% and 26%, respectively, reflecting market pessimism regarding the company's future prospects and potentially leading to further erosion of investor confidence.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating whether Simulation Plus, Inc. violated securities laws and breached fiduciary duties, indicating potential governance issues that could undermine investor confidence.
- Declining Financial Performance: In Q3 2025, Simulation Plus reported a net loss of $67.3 million and a $77.2 million non-cash impairment charge, highlighting the company's vulnerability amid market uncertainties, which may lead to further stock price declines.
- Auditor Dismissal: The company dismissed its auditor Grant Thornton LLP due to the inability to finalize financial reporting, reflecting significant deficiencies in internal controls and financial reporting that could attract more regulatory scrutiny.
- Stock Price Volatility: In June and July 2025, Simulation Plus's stock fell over 24% and 26% respectively due to financial warnings and disappointing results, significantly impacting shareholder returns and potentially increasing the likelihood of class action lawsuits.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating whether Simulation Plus, Inc. violated securities laws and breached fiduciary duties, potentially exposing executives to legal liabilities and impacting corporate governance.
- Declining Financial Performance: In Q3 2025, Simulation Plus reported a net loss of $67.3 million and a non-cash impairment charge of $77.2 million, highlighting the company's vulnerability amid market uncertainties, which may affect future financing capabilities.
- Auditor Dismissal: The company disclosed the dismissal of its auditor, Grant Thornton LLP, due to the inability to finalize certain financial reporting matters, exacerbating market concerns over its financial transparency and leading to significant stock price fluctuations.
- Severe Stock Price Volatility: In June and July 2025, Simulation Plus's stock price fell over 24% and 26% respectively due to financial warnings and disappointing results, reflecting a severe lack of investor confidence in the company's future prospects.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating Simulation Plus, Inc. to determine if certain officers and directors violated securities laws and breached fiduciary duties, potentially exposing the company to legal risks and financial losses.
- Stock Price Plunge: On June 11, 2025, Simulation Plus lowered its fiscal 2025 revenue outlook due to market uncertainties, causing its stock to drop over 24% from $26.44 to $20.05, indicating investor concerns about the company's future prospects.
- Disappointing Financial Results: On July 14, 2025, Simulation Plus reported a net loss of $67.3 million for the third quarter and a $77.2 million non-cash impairment charge, leading to a nearly 26% decline in stock price from $17.47 to $12.97, reflecting severe deterioration in the company's financial health.
- Auditor Dismissal: The company disclosed that it could not finalize certain matters in its financial reporting, resulting in the dismissal of its auditor Grant Thornton LLP, a decision that may further undermine investor confidence and exacerbate market concerns regarding corporate governance.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating whether Simulation Plus, Inc. violated securities laws and breached fiduciary duties, indicating potential severe governance issues that could undermine investor confidence.
- Declining Financial Performance: In Q3 FY2025, Simulation Plus reported a net loss of $67.3 million and a non-cash impairment charge of $77.2 million, reflecting operational challenges amid market uncertainties that may lead to further stock price declines.
- Auditor Dismissal Impact: The company dismissed its auditor Grant Thornton LLP due to the inability to finalize its Form 10-Q, highlighting significant deficiencies in internal controls and financial reporting that could trigger additional legal liabilities and shareholder claims.
- Stock Price Volatility: Following the financial reports in June and July 2025, Simulation Plus's stock price fell over 24% and 26%, respectively, raising investor concerns about the company's future prospects and potentially prompting more investors to seek legal recourse.
See More
Simulations Plus Under Investigation for Securities Violations
- Investigation Background: Johnson Fistel, PLLP is investigating potential securities law violations by Simulations Plus, Inc., focusing on whether the company made false or misleading statements regarding its financial outlook, reporting practices, and internal controls, which could significantly impact investors.
- Revenue Guidance Cut: In June 2025, Simulations Plus revised its full-year revenue guidance down from $90 million to $93 million to a range of $76 million to $80 million, primarily due to market uncertainties affecting pharmaceutical and biotechnology clients, leading to a stock price drop of over 24%.
- Significant Financial Losses: In July 2025, Simulations Plus reported a third-quarter net loss of $67.3 million, or $3.35 per diluted share, which included a $77.2 million non-cash impairment charge, indicating a severe deterioration in the company's financial health.
- Audit Firm Dismissal: The company's Audit Committee dismissed Grant Thornton LLP due to unresolved issues related to financial reporting, causing the stock price to plummet nearly 26%, from $17.47 to $12.97 per share, exacerbating investor concerns about the company's governance and financial integrity.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating Simulation Plus, Inc. to determine whether certain officers and directors violated securities laws and fiduciary duties, potentially exposing the company to legal risks and reputational damage.
- Declining Financial Performance: On July 14, 2025, Simulation Plus reported a net loss of $67.3 million for the third quarter, along with a $77.2 million non-cash impairment charge, indicating financial vulnerability amid market uncertainties that could affect future funding capabilities.
- Auditor Dismissal: The company disclosed the dismissal of its auditor, Grant Thornton LLP, due to the inability to finalize certain matters in financial reporting, raising investor concerns about internal controls and financial transparency, which may exacerbate shareholder anxiety.
- Stock Price Volatility: Following the earnings announcements on June 11 and July 15, Simulation Plus's stock price plummeted over 24% and 26%, respectively, reflecting market pessimism regarding the company's future prospects and potentially leading to further erosion of investor confidence.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating whether Simulation Plus, Inc. violated securities laws and breached fiduciary duties, indicating potential governance issues that could undermine investor confidence.
- Declining Financial Performance: In Q3 2025, Simulation Plus reported a net loss of $67.3 million and a $77.2 million non-cash impairment charge, highlighting the company's vulnerability amid market uncertainties, which may lead to further stock price declines.
- Auditor Dismissal: The company dismissed its auditor Grant Thornton LLP due to the inability to finalize financial reporting, reflecting significant deficiencies in internal controls and financial reporting that could attract more regulatory scrutiny.
- Stock Price Volatility: In June and July 2025, Simulation Plus's stock fell over 24% and 26% respectively due to financial warnings and disappointing results, significantly impacting shareholder returns and potentially increasing the likelihood of class action lawsuits.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating whether Simulation Plus, Inc. violated securities laws and breached fiduciary duties, potentially exposing executives to legal liabilities and impacting corporate governance.
- Declining Financial Performance: In Q3 2025, Simulation Plus reported a net loss of $67.3 million and a non-cash impairment charge of $77.2 million, highlighting the company's vulnerability amid market uncertainties, which may affect future financing capabilities.
- Auditor Dismissal: The company disclosed the dismissal of its auditor, Grant Thornton LLP, due to the inability to finalize certain financial reporting matters, exacerbating market concerns over its financial transparency and leading to significant stock price fluctuations.
- Severe Stock Price Volatility: In June and July 2025, Simulation Plus's stock price fell over 24% and 26% respectively due to financial warnings and disappointing results, reflecting a severe lack of investor confidence in the company's future prospects.
See More
Simulation Plus Under Investigation for Securities Violations
- Shareholder Rights Investigation: Robbins LLP is investigating Simulation Plus, Inc. to determine if certain officers and directors violated securities laws and breached fiduciary duties, potentially exposing the company to legal risks and financial losses.
- Stock Price Plunge: On June 11, 2025, Simulation Plus lowered its fiscal 2025 revenue outlook due to market uncertainties, causing its stock to drop over 24% from $26.44 to $20.05, indicating investor concerns about the company's future prospects.
- Disappointing Financial Results: On July 14, 2025, Simulation Plus reported a net loss of $67.3 million for the third quarter and a $77.2 million non-cash impairment charge, leading to a nearly 26% decline in stock price from $17.47 to $12.97, reflecting severe deterioration in the company's financial health.
- Auditor Dismissal: The company disclosed that it could not finalize certain matters in its financial reporting, resulting in the dismissal of its auditor Grant Thornton LLP, a decision that may further undermine investor confidence and exacerbate market concerns regarding corporate governance.
See More
